Press Releases

MIAMI, April 30, 2024 /PRNewswire/ -- The Wealth Flow Conference , brainchild of Dr. Joseph Nantomah, "The Black Mentor," is poised for a triumphant return to Dallas, Texas this August. Mark your calendars from August 23rd to 25th as this premier wealth-building event promises to empower attendees with transformative insights, actionable strategies, and invaluable connections for achieving sustainable prosperity.

... (continue reading...)

FINDLAY, Ohio, April 30, 2024 /PRNewswire/ --

• First-quarter net income attributable to MPC of $937 million, or $2.58 per diluted share; adjusted EBITDA of $3.3 billion

• Net cash provided by operating activities of $1.5 billion; safely and successfully completed largest planned maintenance quarter in MPC history, including at four of its largest refineries

• Advanced midstream growth strategy, with new processing plants in the Marcellus and Permian basins and acquisition... (continue reading...)

SYRACUSE, N.Y.--(BUSINESS WIRE)-- Associated Medical Professionals of NY (A.M.P.) is pleased to announce that internationally recognized radiation oncology physician, researcher and thought leader Steven E. Finkelstein, M.D., DABR, FACRO, has joined its care team as Director of the Center of Advanced Radiation Excellence (CARE) and Director of Radiation Oncology Research.

Associated Medical Professionals of NY spans 18 locations in Central New York, including nine... (continue reading...)

VANCOUVER, BC and LAS VEGAS, NV / ACCESSWIRE / April 30, 2024 / Ovation Science Inc. ("Ovation" or the "Company") (CSE:OVAT)(OTCQB:OVATF), with its proprietary topical and transdermal cannabis products powered by its patented skin delivery technology Invisicare�, today announced the official launch of its topical product line in Nevada with Planet 13 Holdings, Inc. (CSE:PLTH)(OTCQX:PLNH) ("Planet 13"). These products will be available in store, reach customers through... (continue reading...)

SHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of NV-387 is completed successfully and data lock is expected soon.

The Phase 1 clinical trial, protocol number KM-NVCoV2-001, which received approval from the regulatory agency in India for healthy as well as COVID-19 participants, was closed and completed in April by the Drug... (continue reading...)